Replies to post #292 on Novocure Ltd (NVCR)

[dstock07734]

jondoeuk,

Have you even read Dr. Bosch's presentation? Read it carefully. 600 GBM patients received DCVax-L treatment. Play simple math and remind yourself how many patients receiving DCVax-L through compassionate use program. GBM Patients in compassionate use program most likely would received new batch of the vaccine from the recurrent tumor tissue as indicated in the presentation, which means the results are much better than those of p3 trial.

I haven't mentioned about of tens of patients with other types of tumors yet.

The vaccine is an expensive placebo.

What a ludicrous claim!